-
An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models Diabetol. (IF 8.4) Pub Date : 2024-09-09 Tsugumasa Toma, Nobukazu Miyakawa, Yuiichi Arakaki, Takuro Watanabe, Ryosei Nakahara, Taha F. S. Ali, Tanima Biswas, Mikio Todaka, Tatsuya Kondo, Mikako Fujita, Masami Otsuka, Eiichi Araki, Hiroshi Tateishi
-
The islet tissue plasminogen activator/plasmin system is upregulated with human islet amyloid polypeptide aggregation and protects beta cells from aggregation-induced toxicity Diabetol. (IF 8.4) Pub Date : 2024-09-09 Nathalie Esser, Meghan F. Hogan, Andrew T. Templin, Rehana Akter, Brendy S. Fountaine, Joseph J. Castillo, Assam El-Osta, Lakshan Manathunga, Alexander Zhyvoloup, Daniel P. Raleigh, Sakeneh Zraika, Rebecca L. Hull, Steven E. Kahn
-
Pathophysiology and Treatment of Prediabetes and Type 2 Diabetes in Youth Diabetes Care (IF 14.8) Pub Date : 2024-09-09 Fida Bacha, Tamara S. Hannon, Mustafa Tosur, Julie M. Pike, Ashley Butler, Kalie L. Tommerdahl, Philip S. Zeitler
Youth-onset type 2 diabetes is a heterogeneous disease with increasing prevalence in relation to increased rates of obesity in children. It has genetic, epigenetic, social, and environmental determinants. Youth-onset type 2 diabetes is alarming given a rapidly progressive course compared with the course of adult-onset disease, early-onset vascular complications, and long-term exposure to hyperglycemia
-
The Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Antidiabetic Medication under Conditions of Clinical Uncertainty Diabetes Care (IF 14.8) Pub Date : 2024-09-09 James H. Flory, Jessica S. Ancker, Scott Y.H. Kim, Gilad Kuperman, Aleksandr Petrov, Andrew Vickers
OBJECTIVE To explore how the commercially available large language model (LLM) GPT-4 compares to endocrinologists when addressing medical questions when there is uncertainty regarding the best answer. RESEARCH DESIGN AND METHODS This study compared responses from GPT-4 to responses from 31 endocrinologists using hypothetical clinical vignettes focused on diabetes, specifically examining the prescription
-
Comment on the role of interferons in the pathology of beta cell destruction in type 1 diabetes. Diabetol. (IF 8.4) Pub Date : 2024-09-07 Sigurd Lenzen
-
Implicating type 2 diabetes effector genes in relevant metabolic cellular models using promoter-focused Capture-C Diabetol. (IF 8.4) Pub Date : 2024-09-06 Nicholas A. Wachowski, James A. Pippin, Keith Boehm, Sumei Lu, Michelle E. Leonard, Elisabetta Manduchi, Ursula W. Parlin, Martin Wabitsch, Alessandra Chesi, Andrew D. Wells, Struan F. A. Grant, Matthew C. Pahl
-
Lifetime history of gestational diabetes and cognitive function in parous women in midlife Diabetol. (IF 8.4) Pub Date : 2024-09-06 Diana C. Soria-Contreras, Siwen Wang, Jiaxuan Liu, Rebecca B. Lawn, Makiko Mitsunami, Alexandra C. Purdue-Smithe, Cuilin Zhang, Emily Oken, Jorge E. Chavarro
-
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia. Endocr. Rev. (IF 22.0) Pub Date : 2024-09-06 Robert Krysiak,Hedi L Claahsen-van der Grinten,Nicole Reisch,Philippe Touraine,Henrik Falhammar
Treatment of classic congenital adrenal hyperplasia (CAH) is directed at replacing deficient hormones and reducing androgen excess. However, even in the era of early diagnosis and lifelong hormonal substitution, the presence of CAH is still associated with numerous complications and also with increased mortality. The aim of this article was to create an authoritative and balanced review concerning
-
Erratum. Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care 2024;47:1276–1298 Diabetes Care (IF 14.8) Pub Date : 2024-09-06 Moshe Phillip, Peter Achenbach, Ananta Addala, Anastasia Albanese-O’Neill, Tadej Battelino, Kirstine J. Bell, Rachel E.J. Besser, Ezio Bonifacio, Helen M. Colhoun, Jennifer J. Couper, Maria E. Craig, Thomas Danne, Carine de Beaufort, Klemen Dovc, Kimberly A. Driscoll, Sanjoy Dutta, Osagie Ebekozien, Helena Elding Larsson, Daniel J. Feiten, Brigitte I. Frohnert, Robert A. Gabbay, Mary P. Gallagher,
In the article cited above, incorrect affiliation information was given for author Linda A. DiMeglio. The correct affiliation for Linda A. DiMeglio is Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN. The online version of the article (https://doi.org/10.2337/dci24-0042) has been updated to correct the error.
-
Development of a Core Outcome Set for Studies Assessing Interventions for Diabetes-Related Foot Ulceration Diabetes Care (IF 14.8) Pub Date : 2024-09-06 Aleksandra Staniszewska, Frances Game, Jane Nixon, David Russell, David G. Armstrong, Christopher Ashmore, Sicco A. Bus, Jayer Chung, Vivienne Chuter, Ketan Dhatariya, George Dovell, Michael Edmonds, Robert Fitridge, Catherine Gooday, Emma J. Hamilton, Amy Jones, Venu Kavarthapu, Lawrence A. Lavery, Joseph L. Mills, Matilde Monteiro-Soares, Maia Osborne-Grinter, Edgar J.G. Peters, Joseph Shalhoub,
OBJECTIVE Diabetes affects 537 million people globally, with 34% expected to develop foot ulceration in their lifetime. Diabetes-related foot ulceration causes strain on health care systems worldwide, necessitating provision of high-quality evidence to guide their management. Given heterogeneity of reported outcomes, a core outcome set (COS) was developed to standardize outcome measures in studies
-
Comment on the role of interferons in the pathology of beta cell destruction in type 1 diabetes. Reply to Lenzen S [letter] Diabetol. (IF 8.4) Pub Date : 2024-09-05 Decio L. Eizirik, Priscila L. Zimath, Xiaoyan Yi, Arturo Roca Rivada, Sarah J. Richardson
-
Postbiotic impact on host metabolism and immunity provides therapeutic potential in metabolic disease. Endocr. Rev. (IF 22.0) Pub Date : 2024-09-05 Han Fang,Rodrigo Rodrigues E-Lacerda,Nicole G Barra,Dana Kukje Zada,Nazli Robin,Alina Mehra,Jonathan D Schertzer
The gut microbiota influences aspects of metabolic disease, including tissue inflammation, adiposity, blood glucose, insulin, and endocrine control of metabolism. Prebiotics or probiotics are often sought to combat metabolic disease. However, prebiotics lack specificity and can have deleterious bacterial community effects. Probiotics require live bacteria to find a colonization niche sufficient to
-
Utilizing Continuous Glucose Monitoring for Early Detection of Gestational Diabetes and Pregnancy Outcomes in an Asian Population Diabetes Care (IF 14.8) Pub Date : 2024-09-05 Beth S.Y. Lim, Qian Yang, Mahesh Choolani, Daphne S.L. Gardner, Yap Seng Chong, Cuilin Zhang, Shiao-Yng Chan, Ling-Jun Li
OBJECTIVE We explored the potential value of continuous glucose monitoring (CGM) in early pregnancy in predicting gestational diabetes mellitus (GDM) and pregnancy outcomes. RESEARCH DESIGN AND METHODS The study recruited 103 multiethnic Asian pregnant women with overweight/obesity from a hospital-based, prospective cohort. All of them had worn blinded CGM devices in early pregnancy and underwent the
-
Similar early metabolic changes induced by dietary weight loss or bariatric surgery. Reply to Taylor R [letter]. Diabetol. (IF 8.4) Pub Date : 2024-09-05 Jan W Eriksson,Maria J Pereira,Giovanni Fanni,Ulf Risérus,Mark Lubberink,Håkan Ahlström
-
Similar early metabolic changes induced by dietary weight loss or bariatric surgery. Diabetol. (IF 8.4) Pub Date : 2024-09-05 Roy Taylor
-
Maternal Glycemia During Pregnancy and Child Lung Function: A Prospective Cohort Study Diabetes Care (IF 14.8) Pub Date : 2024-09-04 Meng Yang, Zhongqiang Cao, Wenqing Li, Jieqiong Zhou, Jiuying Liu, Yuanyuan Zhong, Yan Zhou, Lingli Sun, Ruizhen Li, Xiaonan Cai, Han Xiao, Aifen Zhou
OBJECTIVE Gestational diabetes mellitus (GDM) is known to be associated with certain respiratory impairments in offspring. However, the specific association between maternal GDM and childhood lung function remains unclear. We examined the association of maternal glycemia, as measured by oral glucose tolerance test (OGTT) values, with childhood lung function outcomes in a birth cohort. RESEARCH DESIGN
-
Dietary patterns during pregnancy and maternal and birth outcomes in women with type 1 diabetes: the Environmental Determinants of Islet Autoimmunity (ENDIA) study Diabetol. (IF 8.4) Pub Date : 2024-09-02 Rebecca L. Thomson, James D. Brown, Helena Oakey, Kirsten Palmer, Pat Ashwood, Megan A. S. Penno, Kelly J. McGorm, Rachel Battersby, Peter G. Colman, Maria E. Craig, Elizabeth A. Davis, Tony Huynh, Leonard C. Harrison, Aveni Haynes, Richard O. Sinnott, Peter J. Vuillermin, John M. Wentworth, Georgia Soldatos, Jennifer J. Couper
-
Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-09-03 Alessandro Grattoni, Gregory Korbutt, Alice A. Tomei, Andrés J. García, Andrew R. Pepper, Cherie Stabler, Michael Brehm, Klearchos Papas, Antonio Citro, Haval Shirwan, Jeffrey R. Millman, Juan Melero-Martin, Melanie Graham, Michael Sefton, Minglin Ma, Norma Kenyon, Omid Veiseh, Tejal A. Desai, M. Cristina Nostro, Marjana Marinac, Megan Sykes, Holger A. Russ, Jon Odorico, Qizhi Tang, Camillo Ricordi
-
A new clinical age of aging research. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-09-02 Zhen Zhang,Renlei Yang,Zhike Zi,Baohua Liu
Aging is a major risk factor for a variety of diseases, thus, translation of aging research into practical applications is driven by the unmet need for existing clinical therapeutic options. Basic and translational research efforts are converging at a critical stage, yielding insights into how fundamental aging mechanisms are used to identify promising geroprotectors or therapeutics. This review highlights
-
The direct targets of metformin in diabetes and beyond. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-09-02 Luxia Yao,Lei Wang,Runshuai Zhang,Alexander A Soukas,Lianfeng Wu
Metformin, an oral antihyperglycemic drug that has been in use for over 60 years, remains a first-line therapy for type 2 diabetes (T2D). Numerous studies have suggested that metformin promotes health benefits beyond T2D management, including weight loss, cancer prevention and treatment, and anti-aging, through several proposed mechanistic targets. Here we discuss the established effects of metformin
-
Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE) Diabetol. (IF 8.4) Pub Date : 2024-08-31 Fidelma Dunne, Christine Newman, Alberto Alvarez-Iglesias, Paula O’Shea, Declan Devane, Paddy Gillespie, Aoife Egan, Martin O’Donnell, Andrew Smyth
-
The future is here: an overview of technology in diabetes Diabetol. (IF 8.4) Pub Date : 2024-08-30 Ritwika Mallik, Partha Kar, Hindrik Mulder, Anna Krook
-
Global experiences and personal narratives on diabetes technology and access Diabetol. (IF 8.4) Pub Date : 2024-08-30 Renza Scibilia, Niki Breslin-Brooker, Chris Bright, Tinotenda Dzikiti, Salih Hendricks, Vilgot Shik, Jazz Sethi, Sara Vanhentenryk, Lakshminarayana Varimadugu, Jurgen Vercauteren
-
Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes Diabetes Care (IF 14.8) Pub Date : 2024-08-30 Yoko Narasaki, Kamyar Kalantar-Zadeh, Andrea C. Daza, Amy S. You, Alejandra Novoa, Renal Amel Peralta, Man Kit Michael Siu, Danh V. Nguyen, Connie M. Rhee
OBJECTIVE In the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional self-monitored blood glucose and results in reduced hypo-/hyperglycemia and increased time-in-target glucose range. However, accuracy of CGM versus blood glucose is not well established in hemodialysis patients. RESEARCH DESIGN AND METHODS Among 31 maintenance
-
Effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease Diabetol. (IF 8.4) Pub Date : 2024-08-29 Donna S.-H. Lin, Jen-Kuang Lee, Kuan-Chih Huang, Ting-Tse Lin, Hao-Yun Lo
-
Neurons in the diagonal band of Broca moderate food intake Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-08-29 Senegal Carty
Identifying neurological mechanisms that regulate feeding behaviour could help to advance the treatment and prevention of obesity and eating disorders. New research in mice has identified and localized a population of neurons that promotes eating to satiate hunger and reduces the desire to eat simply for pleasure. One subset of these DBBPENK neurons projects from the DBB to the paraventricular nucleus
-
The promising potential of gene therapy for diabetes mellitus Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-08-29 Stefan R. Bornstein, J. Fraser Wright, Charlotte Steenblock
Gene therapy holds tremendous promise for treating a wide range of hereditary and acquired diseases by delivering exogenous therapeutic nucleotide sequences into specific cells or tissues. Recent advances support the notion that gene therapy could offer a long-term cure for diabetes mellitus, something that current conventional pharmacotherapies cannot achieve.
-
Astrocyte involvement in metabolic regulation and disease. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-08-29 Muhammad Naveed,Kathryn Smedlund,Qi-Gang Zhou,Weikang Cai,Jennifer W Hill
Astrocytes, the predominant glial cell type in the mammalian brain, influence a wide variety of brain parameters including neuronal energy metabolism. Exciting recent studies have shown that obesity and diabetes can impact on astrocyte function. We review evidence that dysregulation of astrocytic lipid metabolism and glucose sensing contributes to dysregulation of whole-body energy balance, thermoregulation
-
Erratum. 189-OR: Food Insecurity and Inability to Obtain Recommended Medications, Diabetes Technology, and Multidisciplinary Services in Youth and Young Adults with Diabetes. Diabetes 2024;73 (Suppl. 1):189-OR Diabetes (IF 6.2) Pub Date : 2024-08-29 Angela D. Liese, Emmanuel F. Julceus, Caroline Rudisill, Faisal Malik, Kate Flory, Edward A. Frongillo, Katherine A. Sauder, Jason A. Mendoza
In the abstract cited above, author Nadine El Kalach was inadvertently omitted from the author list. The full, correct author list is as follows: Nadine El Kalach, Emmanuel F. Julceus, Caroline Rudisill, Faisal Malik, Kate Flory, Edward A. Frongillo, Katherine A. Sauder, Jason A. Mendoza, and Angela D. Liese. All authors approve the addition and the order of the revised author list. The authors apologize
-
Diabetes, Prediabetes, and Brain Aging: The Role of Healthy Lifestyle Diabetes Care (IF 14.8) Pub Date : 2024-08-28 Abigail Dove, Jiao Wang, Huijie Huang, Michelle M. Dunk, Sakura Sakakibara, Marc Guitart-Masip, Goran Papenberg, Weili Xu
OBJECTIVE Diabetes is a well-known risk factor for dementia. We investigated the association between (pre)diabetes and older brain age and whether this can be attenuated by modifiable lifestyle behaviors. RESEARCH DESIGN AND METHODS The study included 31,229 dementia-free adults from the UK Biobank between the ages of 40 and 70. Glycemic status (normoglycemia, prediabetes, or diabetes) was ascertained
-
Glucagon Stimulation Test and Insulin Secretory Capacity in Clinical Assessment of Incretin-Based Therapy for Diabetes Diabetes (IF 6.2) Pub Date : 2024-08-28 Takuya Haraguchi, Yuji Yamazaki, Hitoshi Kuwata, Ryota Usui, Yoshiyuki Hamamoto, Yutaka Seino, Daisuke Yabe, Yuichiro Yamada
Evaluation of insulin secretory capacity is essential to understand the pathophysiological condition of individuals with diabetes and to assess the efficacy of drugs used in treatment of the disease. The 1 mg intravenous glucagon stimulation test (GST) is widely used to evaluate residual β cell function; we previously reported that GST assessment of insulin secretory capacity is useful in assessing
-
The complexity of adipocyte heterogeneity Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-08-27 Claire Greenhill
It is well known that adipocytes are heterogeneous, and research about how best to identify and categorize adipocyte subclasses is ongoing. Thermogenic adipocytes are generally identified by the presence of UCP1; the futile creatine cycle is also an important thermogenic process in these cells. However, a lack of suitable models — particularly for beige adipose tissue — has stalled research into the
-
Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data Diabetes Care (IF 14.8) Pub Date : 2024-08-27 Ariane Jullien, Clément Jambon-Barbara, Jean-Luc Cracowski, Brian L. Claggett, Anne-Laure Borel, Charles Khouri, Matthieu Roustit
OBJECTIVE Multiregional trials are designed under the assumption that treatment effect applies to the entire target population, yet several factors may introduce geographic heterogeneity in treatment effect. We explored whether such variations exist in trials assessing the efficacy of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in major cardiovascular events (MACE) in type 2 diabetes. RESEARCH
-
Effectiveness of Multilevel and Multidomain Interventions to Improve Glycemic Control in U.S. Racial and Ethnic Minority Populations: A Systematic Review and Meta-analysis Diabetes Care (IF 14.8) Pub Date : 2024-08-27 Eli M. Falk, Erin M. Staab, Amber N. Deckard, Sofia I. Uranga, Nikita C. Thomas, Wen Wan, Andrew J. Karter, Elbert S. Huang, Monica E. Peek, Neda Laiteerapong
BACKGROUND Racial and ethnic disparities in type 2 diabetes outcomes are a major public health concern. Interventions targeting multiple barriers may help address disparities. PURPOSE To conduct a systematic review and meta-analysis of diabetes self-management education (DSME) interventions in minority populations. We hypothesized that interventions addressing multiple levels (individual, interpersonal
-
The unexpected role of GIP in transforming obesity treatment. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-08-27 Inuk Zandvakili,Diego Perez-Tilve
Despite sharing incretin activity with glucagon-like peptide 1 (GLP-1), the development of gastric inhibitory polypeptide (GIP)-based drugs has been hindered by the minor effects of native GIP on appetite and body weight and genetic studies associating loss-of-function with reduced obesity. Yet, pharmacologically optimized GIP-based molecules have demonstrated profound weight lowering benefits of GIPR
-
Emerging interactions between mitochondria and NAD+ metabolism in cardiometabolic diseases. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-08-27 Azadeh Nasuhidehnavi,Weronika Zarzycka,Ignacy Górecki,Ying Ann Chiao,Chi Fung Lee
Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme for redox reactions and regulates cellular catabolic pathways. An intertwined relationship exists between NAD+ and mitochondria, with consequences for mitochondrial function. Dysregulation in NAD+ homeostasis can lead to impaired energetics and increased oxidative stress, contributing to the pathogenesis of cardiometabolic diseases.
-
Clinical Outcomes in Pediatric Patients With Type 1 Diabetes With Early Versus Late Diagnosis: Analysis From the DPV Registry Diabetes Care (IF 14.8) Pub Date : 2024-08-26 Johanna Hammersen, Sascha R. Tittel, Clemens Kamrath, Katharina Warncke, Angela Galler, Ulrike Menzel, Melanie Hess, Thomas Meißner, Beate Karges, Reinhard W. Holl
OBJECTIVE This study was conducted to evaluate the effects of early clinical diagnosis of type 1 diabetes by comparison of clinical parameters at diagnosis and during follow-up in patients with pediatric type 1 diabetes with early, intermediate, and late diagnosis. RESEARCH DESIGN AND METHODS In a population-based analysis, data on 14,292 pediatric patients with type 1 diabetes diagnosed between 2015
-
Walking the VLDL tightrope in cardiometabolic diseases. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-08-26 Mindy Kim,Ze Zheng
Very-low-density lipoprotein (VLDL), a triglyceride-rich lipoprotein secreted by hepatocytes, is pivotal for supplying peripheral tissues with fatty acids for energy production. As if walking on a tightrope, perturbations in the balance of VLDL metabolism contribute to cardiometabolic dysfunction, promoting pathologies such as cardiovascular disease (CVD) or metabolic dysfunction-associated steatotic
-
Patient-derived organoid models to decode liver pathophysiology. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-08-26 Benjamin J Dwyer,Janina E E Tirnitz-Parker
Liver diseases represent a growing global health challenge, and the increasing prevalence of obesity and metabolic disorders is set to exacerbate this crisis. To meet evolving regulatory demands, patient-specific in vitro liver models are essential for understanding disease mechanisms and developing new therapeutic approaches. Organoid models, which faithfully recapitulate liver biology, can be established
-
Visceral adipocyte-derived extracellular vesicle miR-27a-5p elicits glucose intolerance by inhibiting pancreatic β-cell insulin secretion Diabetes (IF 6.2) Pub Date : 2024-08-26 Yaqin Zhang, Bin Qian, Yang Yang, Fandi Niu, Changsong Lin, Honglei Yuan, Jianan Wang, Tijun Wu, Yixue Shao, Shulin Shao, Aiming Liu, Jingwen Wu, Peng Sun, Xiaoai Chang, Yan Bi, Wei Tang, Yunxia Zhu, Fang Chen, Dongming Su, Xiao Han
Pancreatic β-cell dysfunction caused by obesity can be associated with alterations in the levels of microRNAs (miRNAs). However, the role of miRNAs in such processes remains elusive. Here, we show that pancreatic islet miR-27a-5p, which is markedly increased in obese mice and impairs insulin secretion, is mainly delivered by visceral adipocyte-derived extracellular vesicles (EVs). Depleting miR-27a-5p
-
Genetics of glucose homeostasis in pregnancy and postpartum Diabetol. (IF 8.4) Pub Date : 2024-08-24 William L. Lowe, Alan Kuang, M. Geoffrey Hayes, Marie-France Hivert, Denise M. Scholtens
-
Novel secreted regulators of glucose and lipid metabolism in the development of metabolic diseases Diabetol. (IF 8.4) Pub Date : 2024-08-24 Lianna W. Wat, Katrin J. Svensson
-
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care Diabetol. (IF 8.4) Pub Date : 2024-08-23 Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, Enzo Bonora, Agostino Consoli, Bruno Fattor, Mauro Rigato, Federica Turchi, Stefano Del Prato, Angelo Avogaro, Anna Solini
-
The cortisol awakening response: regulation and functional significance. Endocr. Rev. (IF 22.0) Pub Date : 2024-08-23 Tobias Stalder,Henrik Oster,James L Abelson,Katharina Huthsteiner,Tim Klucken,Angela Clow
In healthy individuals, the majority of cortisol secretion occurs within several hours surrounding morning awakening. A highly studied component of this secretory period is the cortisol awakening response (CAR), the rapid increase in cortisol levels across the first 30-45 min after morning awakening. This strong cortisol burst at the start of the active phase has been proposed to be functional in preparing
-
Per- and polyfluoroalkyl substances as persistent pollutants with metabolic and endocrine-disrupting impacts. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-08-23 Lucas Gaillard,Robert Barouki,Etienne Blanc,Xavier Coumoul,Karine Andréau
The widespread use of per- and polyfluoroalkyl substances (PFASs), and their resistance to degradation, renders human exposure to them inevitable. PFAS exposure disturbs endocrine function, potentially affecting cognitive development in newborns through thyroid dysfunction during pregnancy. Recent studies reveal varying male and female reproductive toxicity across PFAS classes, with alternative analogs
-
New anti-inflammatory mechanism of glucocorticoids uncovered. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-08-23 Carolyn L Cummins,Ido Goldstein
Glucocorticoids (GCs) are potent anti-inflammatory drugs. A new study by Auger et al. found that GCs increase itaconate, an anti-inflammatory tricarboxylic acid (TCA) cycle intermediate, by promoting movement of cytosolic pyruvate dehydrogenase (PDH) to mitochondria. Itaconate was sufficient for mediating the anti-inflammatory effects of GCs in mice, overriding the notion that nuclear glucocorticoid
-
Exploring the heterogeneous targets of metabolic aging at single-cell resolution. Trends Endocrin. Met. (IF 11.4) Pub Date : 2024-08-23 Shuhui Sun,Mengmeng Jiang,Shuai Ma,Jie Ren,Guang-Hui Liu
Our limited understanding of metabolic aging poses major challenges to comprehending the diverse cellular alterations that contribute to age-related decline, and to devising targeted interventions. This review provides insights into the heterogeneous nature of cellular metabolism during aging and its response to interventions, with a specific focus on cellular heterogeneity and its implications. By
-
Müller cells harboring exosomal lncRNA OGRU modulates microglia polarization in diabetic retinopathy via serving as miRNA sponges Diabetes (IF 6.2) Pub Date : 2024-08-23 ShuHua Fu, WenJing Sun, Lu Liu, JiPing Xiao, Jian Xiong, YaoYun Hu, QianQian Zhou, XiaoLong Yin
Diabetic retinopathy (DR) is one of the most common complications of diabetes mellitus which is associated with visual loss and blindness worldwide. However, the effective treatments for both early- and late-stage DR remains lacking. A streptozotocin (STZ)-induced diabetic mice model and high glucose (HG)-treated Müller cell model were established. M1/M2 microglia polarization was assessed by immunofluorescence
-
Machine learning-based reproducible prediction of type 2 diabetes subtypes Diabetol. (IF 8.4) Pub Date : 2024-08-21 Hayato Tanabe, Masahiro Sato, Akimitsu Miyake, Yoshinori Shimajiri, Takafumi Ojima, Akira Narita, Haruka Saito, Kenichi Tanaka, Hiroaki Masuzaki, Junichiro J. Kazama, Hideki Katagiri, Gen Tamiya, Eiryo Kawakami, Michio Shimabukuro
-
New insights into the regulation of GIPR signalling Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-08-22 Yusman Manchanda, Alejandra Tomas
Two recent studies have unravelled novel modes of glucose-dependent insulinotropic polypeptide receptor (GIPR) signalling regulation. Kizilkaya et al. characterized the effect of changes in β-arrestin 2 coupling with naturally occurring GIPR coding variants, whereas Regmi et al. investigated GIPR expression profiles and functional regulation in adipocytes.
-
Leptin activation of dorsal raphe neurons inhibits feeding behavior Diabetes (IF 6.2) Pub Date : 2024-08-22 Nicholas David Maxwell, Cora Elizabeth Smiley, Alia Tereza Sadek, Frances Zoe Loyo-Rosado, Daniel Christian Giles, Victoria Alice Macht, Jennifer Lynn Woodruff, Donzelle Lee Taylor, Victoria Marie Glass, Steven Peter Wilson, Lawrence Patrick Reagan, James Robert Fadel, Claudia Alejandra Grillo
Leptin is a homeostatic regulatory element that signals the presence of adipocyte energy stores, reduces food intake, and increases energy expenditure. Similarly, serotonin (5- HT), a signaling molecule found in both the central and peripheral nervous systems, also controls food intake. Using neuronal tract-tracing, pharmacological and optogenetics approaches, and in vivo microdialysis, combined with
-
Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop Diabetes (IF 6.2) Pub Date : 2024-08-22 Carla J. Greenbaum, Gerald T. Nepom, Lauren K. Wood-Heickman, Diane K. Wherrett, Linda A. DiMeglio, Kevan C. Herold, Jeffrey P. Krischer
The approval of teplizumab to delay the onset of type 1 diabetes is an important inflection point in the decades long pursuit to treat the cause of the disease rather than its symptoms. NIDDK convened a workshop of the Diabetes Mellitus Interagency Coordinating Committee titled “Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes” to review this accomplishment and identify
-
The effect of metformin on peripheral nerve morphology in type 2 diabetes: a cross-sectional observational study Diabetes (IF 6.2) Pub Date : 2024-08-21 Roshan Dhanapalaratnama, Tushar Issar, Leiao Leon Wang, Darren Tran, Ann M. Poynten, Kerry-Lee Milner, Natalie CG. Kwai, Arun V. Krishnan
Diabetic peripheral neuropathy (DPN) affects around 50% of the 500 million people with type 2 diabetes worldwide and is considered disabling and irreversible. The present study was undertaken to assess the effect of metformin on peripheral neuropathy outcomes in type 2 diabetes. 69 type 2 diabetes participants receiving metformin were recruited and underwent clinical assessment, peripheral nerve ultrasound
-
Pancreatic β cell TRAPδ deficiency reduces insulin production but improves insulin sensitivity Diabetes (IF 6.2) Pub Date : 2024-08-21 Jiyun Guo, Yanshu Yang, Ning Xu, Xin Li, Ying Yang, Wenli Feng, Yuanyuan Ye, Xiaoxi Xu, Jingqiu Cui, Ming Liu, Yumeng Huang
The translocon-associated protein-δ (TRAPδ) plays a role in insulin biosynthesis within pancreatic β cells. However, its pathophysiological significance in maintaining islet β cell function and glucose homeostasis remains unclear. In this study, we generated a mouse model featuring pancreatic β cell-specific deletion of TRAPδ (TRAPδ βKO). Our findings revealed that TRAPδ βKO resulted in decreased circulating
-
Food additive emulsifiers and risk of type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Xi Fu, Yiwen Yuan, Yiqun Deng, Yu Sun
-
Reasons to not rethink the label anti-obesity medication Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Richard Armitage
-
Meat consumption and incident type 2 diabetes: an individual-participant federated meta-analysis of 1·97 million adults with 100 000 incident cases from 31 cohorts in 20 countries Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Chunxiao Li PhD, Tom R P Bishop ME, Fumiaki Imamura PhD, Stephen J Sharp MSc, Matthew Pearce PhD, Soren Brage PhD, Prof Ken K Ong FRCPCH, Prof Habibul Ahsan MD, Prof Maira Bes-Rastrollo PhD, Prof Joline W J Beulens PhD, Nicole den Braver PhD, Prof Liisa Byberg PhD, Scheine Canhada PhD, Prof Zhengming Chen DPhil, Hsin-Fang Chung PhD, Adrian Cortés-Valencia PhD, Luc Djousse MD, Jean-Philippe Drouin-Chartier
Meat consumption could increase the risk of type 2 diabetes. However, evidence is largely based on studies of European and North American populations, with heterogeneous analysis strategies and a greater focus on red meat than on poultry. We aimed to investigate the associations of unprocessed red meat, processed meat, and poultry consumption with type 2 diabetes using data from worldwide cohorts and
-
A roadmap for integrating mental health and diabetes services Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Khalida Ismail, Marietta Stadler, Melissa Holloway, Jonathan Valabhji
-
Food additive emulsifiers and risk of type 2 diabetes – Authors' reply Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Bernard Srour, Clara Salame, Mathilde Touvier
-
Meat consumption and type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-08-20 Dagfinn Aune